Promising Results Anchor Tobira's New CCR5 As Potent Player Among Future HIV Treatments on the Horizon
HIV EXPERTS AVAILABLE FOR INTERVIEW
The following experts are available to provide insights and perspective on the evolving landscape of HIV treatments, the relevance of CCR5s and potential unique properties of TBR-652, based on preliminary data presented at CROI.
/PRNewswire -- Feb. 17/
-- Calvin Cohen, MD, M.Sc., Director of Research, Community Research Initiative of New England -- Kathleen Squires, MD, Professor of Medicine, Jefferson Medical College -- Gerd Fatkenheuer, MD, Head of Infectious Disease, University of Cologne -- Alan Landay, PhD, Director, Developmental Center for AIDS Research -- Jerome Ernst, MD, Medical Director, AIDS Community Research Initiative of America
SOURCE Tobira Therapeutics, Inc.
You May Also Like